News

Evommune licenses oral VAV1 degrader EVO570 from Hinova in deal worth up to $1.1B

What happened: On 4 November 2026, Evommune signed an exclusive licence agreement with Hinova Pharmaceuticals granting Evommune worldwide rights, outside Greater China, to develop, manufacture and commercialise EVO570 (formerly HC118; known as HP570 in Greater China), an investigational oral "molecular glue" drug. Evommune pays $30 million upfront ($20 million in cash plus $10 million in pre-funded warrants), with up to approximately $1.1 billion in development, regulatory and commercial milestones plus tiered royalties on sales outside Greater China. A Phase 1 trial is expected to begin imminently, and Evommune plans to start a Phase 2 trial in rheumatoid arthritis in 2027.

Why it matters: EVO570 is designed to selectively destroy VAV1, a signalling protein that drives T- and B-cell activation underlying many chronic inflammatory and autoimmune diseases. Unlike JAK enzymes, the target of several current therapies, VAV1 is found almost exclusively in immune cells — a potential route to similar efficacy with a better safety profile. The drug works as a molecular glue degrader, tethering VAV1 to the cell's protein-disposal machinery so it is broken down. Hinova, headquartered in Chengdu, China (SSE: 688302), has one product already approved in China for prostate cancer and a pipeline spanning traditional small molecules, PROTAC degraders and molecular glues. IND applications for EVO570 have been submitted in China and accepted in the United States.

Read more: Business Wire, 4 November 2026

More top stories